The demand for higher efficiency in regulatory processes has paved the way for innovative technologies such as Robotic Process Automation (RPA). Merck Life Sciences has taken the initiative to enhance its regulatory processes with RPA. RPA enables the automation of monotonous and repetitive activities, ensuring regulatory compliance, and reducing the risk of human error.
The use of RPA in regulatory processes is becoming increasingly common. RPA is an innovative technology that enables organizations to automate complex and repetitive tasks, making it a valuable tool in achieving regulatory compliance in many industries. In the life sciences industry specifically, regulatory compliance is a top priority, and companies such as Merck Life Sciences have implemented RPA to streamline their regulatory workflows and ensure that all regulatory requirements are met.
Benefits of RPA in Reducing Human Error and Automating Complex Activities
Human error can have disastrous consequences in the life sciences industry. The use of RPA to reduce human error and automate complex activities enables Merck to ensure compliance and minimize the potential for errors. By automating regulatory processes, Merck can work more efficiently, reduce operational costs, and avoid compliance violations.
Timeline of the initiative
The initiative began in 2021 and it took two years to implement the solution. By December 2022, the project had covered 23 geographies and 43 regulatory processes, including trade compliance, cross-country logistics, and regulatory management.
Coverage of 23 Geographies and 43 Processes
Merck’s RPA initiative has been implemented across 23 geographies and 43 regulatory processes. This comprehensive approach to automation ensures that all regulatory requirements are met consistently. The company’s RPA deployment has enabled it to standardize its processes, reducing the potential for errors and inconsistencies.
Use of Unattended Bots from Automation Anywhere
Automation Anywhere’s unattended bots formed the backbone of Merck’s RPA initiative. These bots helped automate and streamline the creation, management, and distribution of the company’s regulatory processes. The unattended bots enabled Merck to automate complex regulatory workflows, reduce manual intervention, and ensure accuracy across the board.
Delegation of Monotonous Tasks to RPA, Allowing Regulatory SMEs to Focus on Higher-Value Operations
Merck’s RPA initiative has helped the company’s regulatory subject matter experts (SMEs) focus on higher-value tasks by delegating monotonous chores to RPA. The automation of repetitive tasks has enabled the SMEs to focus their expertise on more valuable tasks that require human intervention, such as decision-making and problem-solving.
Saving 121K Human Hours and Increasing Product Sales by Millions of Euros
Merck’s RPA initiative has delivered significant cost savings. By automating repetitive tasks, the company has saved 121,000 human hours, allowing it to allocate more time toward other valuable tasks. This increased efficiency has enabled Merck to project an increase in its product sales by millions of euros over the next five years based on commercial projections.
Addressing the Need for Handling Unstructured Data and Decision-Making Processes
The handling of unstructured data and decision-making processes is two crucial challenges facing the life sciences industry. Merck’s RPA initiative addresses these challenges by automating repetitive tasks and freeing up regulatory SMEs to focus on decision-making and problem-solving. The implementation of RPA has helped ensure regulatory compliance through consistent data handling, analysis, and decision-making.
Possibility of Cognitive Capabilities Replacing Rule-Based Automation in the Future.
Improvements in cognitive capabilities may eventually replace rule-based automation in the future. The life sciences industry is continually evolving, and technologies such as Artificial Intelligence (AI) and Machine Learning (ML) are already transforming regulatory compliance. As cognitive capabilities continue to advance, it is possible that rule-based automation will become obsolete in time.
Merck has successfully implemented an RPA initiative that has streamlined its regulatory processes, reduced the risk of human error, and increased efficiency. By using unattended bots from Automation Anywhere, the company has automated the creation, management, and distribution of its regulatory processes, resulting in significant cost savings. By delegating monotonous tasks to RPA, Merck’s regulatory subject matter experts can focus on higher-value activities that require human intervention. The development of cognitive capabilities may eventually replace rule-based automation in the future, further enhancing regulatory compliance.